SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financi...(Deferred rent ...)

Date:3/11/2009

Deferred rent 310,010 - Total liabilities 1,328,524 1,535,435 Commitments and Contingencies - - Stockholders' Equity Preferred stock, authorized 5,000,000 shares, $0.01 par value, none issued or outstanding - - Common stock, authorized 100,000,000 shares, $0.001 par value, 41,130,270 and 40,991,385 issued and outstanding as of December 31, 2008 and 2007, respectively 41,130 40,991 Additional contributed capital 71,255,901 69,945,666 Accumulated deficit (63,975,066) (57,834,638) Total stockholders' equity 7,321,965 12,152,019 $8,650,489 $13,687,454 SCOLR Pharma, Inc. STATEMENTS OF OPERATIONS Three months ended Twelve months ended December 31, December 31, ------------- ------------- 2008 2007 2008 2007 ---- ---- ---- ---- Revenues Royalty $176,885 $222,334 $958,320 $1,177,484 Research and development - - - 621,222 Licensing fees - - - 173,077 Total Revenues 176,885 222,334 958,320 1,971,783 Operating Expenses Marketing and selling 127,096 262,920 672,675 936,696 Research and development 1,880,515 2,358,120 6,268,152 7,768,
'/>"/>

SOURCE SCOLR Pharma, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
5. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
6. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
7. China Biopharma, Inc. Announces New Plan of Operation
8. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
9. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
10. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
11. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors